Study · Randomized controlled trial · n = 45 · 2013

5 results

Exenatide and the treatment of patients with Parkinson's disease.

Aviles-Olmos I, Dickson J, Kefalopoulou Z, Djamshidian A, Ell P, Soderlund T, Whitton P, Wyse R, Isaacs T, Lees A, Limousin P, Foltynie T

The Journal of clinical investigation1 Jun 2013Cited by 440 (Europe PMC)

PMID23728174PMCIDPMC3668846DOI10.1172/jci68295PepBankPUB-23728174

Source link PubMedAsk about this study

Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

01HumanRandomized controlled trialEfficacy outcome
In Parkinson's disease, exenatide improved MDS-UPDRS by 2.7 points versus a 2.2-point decline in controls at 12 months.
In plain wordsIn Parkinson's disease, motor scores improved with exenatide while control scores worsened.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseMDS-UPDRS change at 12 months
Study
n = 45
Comparator
Control group
Outcome group
Exercise and physical function · Nervous system and cognition
Studied dose
Dose not stated · subcutaneous · 12 monthsAs given in this study (human).
Measurements
MDS-UPDRS improvement
2.7 points
exenatide group, 12 months
MDS-UPDRS decline
2.2 points
control group, 12 months
Source sentences
Summary
Exenatide-treated patients had a mean improvement at 12 months on the MDS-UPDRS of 2.7 points, compared with mean decline of 2.2 points in control patients (P = 0.037).
1 context sentence(design, population, supporting numbers)
Summary · context
As a proof of concept, using a single-blind trial design, we evaluated the progress of 45 patients with moderate Parkinson's disease (PD), randomly assigned to receive subcutaneous exenatide injection for 12 months or to act as controls.
Report a problemFND-2372817404
02HumanRandomized controlled trialEfficacy outcome
In Parkinson's disease, single-blinded ratings suggested cognitive improvements with exenatide compared with controls.
In plain wordsIn Parkinson's disease, ratings suggested better cognition with exenatide than in controls.
Peptide
Exenatide (exendin-4)
Outcome
IncreaseCognitive measures
Study
n = 45
Comparator
Control group
Outcome group
Cognition and memory · Nervous system and cognition
Studied dose
Dose not stated · subcutaneous · 12 monthsAs given in this study (human).
Source sentences
Summary
Single-blinded rating of the exenatide group suggested clinically relevant improvements in PD across motor and cognitive measures compared with the control group.
1 context sentence(design, population, supporting numbers)
Summary · context
As a proof of concept, using a single-blind trial design, we evaluated the progress of 45 patients with moderate Parkinson's disease (PD), randomly assigned to receive subcutaneous exenatide injection for 12 months or to act as controls.
Report a problemFND-2372817405
03HumanRandomized controlled trialSafety outcome
In patients with Parkinson's disease, exenatide was well tolerated.
In plain wordsIn patients with Parkinson's disease, exenatide was well tolerated.
Peptide
Exenatide (exendin-4)
Outcome
Not applicableTolerability
Study
n: not reported in source
Outcome group
Adverse events · Nervous system and cognition
Studied dose
Dose not stated · subcutaneous · 12 monthsAs given in this study (human).
Source sentences
Summary
Exenatide was well tolerated, although weight loss was common and l-dopa dose failures occurred in a single patient.
1 context sentence(design, population, supporting numbers)
Summary · context
As a proof of concept, using a single-blind trial design, we evaluated the progress of 45 patients with moderate Parkinson's disease (PD), randomly assigned to receive subcutaneous exenatide injection for 12 months or to act as controls.
Report a problemFND-2372817401
04HumanRandomized controlled trialSafety outcome
In patients with Parkinson's disease receiving exenatide, weight loss was common.
In plain wordsIn patients with Parkinson's disease receiving exenatide, weight loss was common.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseWeight loss
Study
n: not reported in source
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated · subcutaneous · 12 monthsAs given in this study (human).
Source sentences
Summary
Exenatide was well tolerated, although weight loss was common and l-dopa dose failures occurred in a single patient.
1 context sentence(design, population, supporting numbers)
Summary · context
As a proof of concept, using a single-blind trial design, we evaluated the progress of 45 patients with moderate Parkinson's disease (PD), randomly assigned to receive subcutaneous exenatide injection for 12 months or to act as controls.
Report a problemFND-2372817402
05HumanRandomized controlled trialSafety outcome
In patients with Parkinson's disease receiving exenatide, l-dopa dose failures occurred in a single patient.
In plain wordsIn patients with Parkinson's disease receiving exenatide, one patient had l-dopa dose failures.
Peptide
Exenatide (exendin-4)
Outcome
Not applicableL-dopa dose failures
Study
n: not reported in source
Outcome group
Adverse events · Nervous system and cognition
Studied dose
Dose not stated · subcutaneous · 12 monthsAs given in this study (human).
Source sentences
Summary
Exenatide was well tolerated, although weight loss was common and l-dopa dose failures occurred in a single patient.
1 context sentence(design, population, supporting numbers)
Summary · context
As a proof of concept, using a single-blind trial design, we evaluated the progress of 45 patients with moderate Parkinson's disease (PD), randomly assigned to receive subcutaneous exenatide injection for 12 months or to act as controls.
Report a problemFND-2372817403

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials3

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

3 trials · 1 completed · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 2Results postedNCT04431713

Exenatide Once-weekly as a Treatment for Multiple System Atrophy

University College, Londonn = 5016 Sept 2020 to 22 Mar 2024

Multiple System Atrophy

Trial page ClinicalTrials.govUpdated 27 Jun 2025

Status unknownPhase 3NCT02847403

Long-acting Exenatide and Cognitive Decline in Dysglycemic Patients

Azienda Ospedaliero-Universitaria di Parman = 40Feb 2016 to est. 31 Oct 2021

Dysglycemia · Cognitive Deficit

Trial page ClinicalTrials.govUpdated 17 Aug 2021

Status unknownPhase 2NCT01174810

Exendin-4 as a Treatment for Parkinson's Disease - Pilot Study

University College, Londonn = 40Jul 2010 to est. Mar 2013

Parkinson's Disease

Trial page ClinicalTrials.govUpdated 23 Mar 2012

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.